| 摘要 |
1. The use of the thromboxane-synthase inhibiting compounds of the formulae see diagramm : EP0028410,P11,F1 see diagramm : EP0028410,P11,F2 see diagramm : EP0028410,P11,F3 or see diagramm : EP0028410,P11,F4 wherein R is hydrogen, nitro or C2-4 -alkenyl, and R**1 is hydrogen, C1-11 -Alkyl, C1-18 -alkanoyl, phenyl, naphthyl, phenyl, naphthyl, phenalkyl or indol-3-yl-C1-4 -alkyl, mono- or disubstituted by C1-3 -alkoxy, C1-4 -alkyl, nitro, C1-18 -alkanoyl or hydroxy ; R**2 is hydrogen, C1-4 -alkyl, phenalkyl, 3-indolyl optionally substituted in the 2-position by straight-chain or branched C1-4 -alkyl ; phenyl, naphthyl or 2-hydroxy-1-naphthylmethylenehydrazino ; R**3 is phenylthio, naphthylthio or C1-11 -alkoxy-oxalylmethyl ; R**4 is carboxy or straight-chain or branched C1-4 -alkyl, R**5 is straight-chain or branched C1-4 -alkyl, R**6 is monochlorinated benzoyl and R**7 is C1-4 -alkoxy ; a salt of a compound of formula I, II or III with a pharmaceutically usable acid, or of the thromboxane-synthase inhibiting compounds from the following group : 3-(5-tetrazolyl)-thioxanthen-9-one, 10,10-dioxide, 1,2-diphenyl-4-[2-(phenyl-sulphinyl)-ethyl]-3,5- -pyrazolidinedione, 1-isopropyl-7-methyl-4-phenyl-2[1H]-quinazolinone and 7-isopropoxy-9-oxo-xanthene-2-carboxylic acid for the manufacture of a medicament for the treatment of obesity and of the lowering of the insulin level. |
